Drug intelligence / Profile preview

SG6001

Development stage: Preclinical
Lead developer: Shenzhen Sungening Biological
Modality: Small Molecules
Administration: Subcutaneous, Oral

Overview

SG6001 is a small molecule inhibitor of Proprotein convertase subtilisin/kexin type 9 (PCSK9) being developed by Sungening (Sungening Biotech). It is intended for the treatment of hypercholesterolemia. By inhibiting PCSK9, the drug prevents the degradation of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, thereby increasing the clearance of LDL cholesterol from the bloodstream. As of 2024, SG6001 is in the IND-enabling stage of development, representing a potential oral alternative to injectable monoclonal antibodies that target the same pathway.

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on SG6001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG6001.

Explore the full profile